IL1B and congenital rubella syndrome: Indeed, as consistently demonstrated by a long series of clinical trials with parental NK cells, patients who received allogenic CAR-NK cell therapy did not develop CRS or neurotoxicity and did not exhibit increased levels of pro-inflammatory cytokines, such as IL-1β, IL-6, and IL-10 [214, 266–268].